The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy
Open Access
- 6 January 2025
- journal article
- review article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 57 (1) , 2447403
Abstract
Cisplatin is a platinum-based drug that is frequently used to treat multiple tumors. The anti-tumor effect of cisplatin is closely related to the tumor immune microenvironment (TIME), which includes several immune cell types, such as the tumor-associated macrophages (TAMs), cytotoxic T-lymphocytes (CTLs), dendritic cells (DCs), myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and natural killer (NK) cells. The interaction between these immune cells can promote tumor survival and chemoresistance, and decrease the efficacy of cisplatin monotherapy. Therefore, various combination treatment strategies have been devised to enhance patient responsiveness to cisplatin therapy. Cisplatin can augment anti-tumor immune responses in combination with immune checkpoint blockers (such as PD-1/PD-L1 or CTLA4 inhibitors), lipid metabolism disruptors (like FASN inhibitors and SCD inhibitors) and nanoparticles (NPs), resulting in better outcomes. Exploring the interaction between cisplatin and the TIME will help identify potential therapeutic targets for improving the treatment outcomes in cancer patients.Keywords
Funding Information
- Scientific Research Fund of Liaoning Provincial Education Department (JYTMS20230577)
- the Horizontal Project Department Fund of the First Affiliated Hospital of Dalian Medical University (2022CR015)
This publication has 206 references indexed in Scilit:
- Cisplatin augments cytotoxic T-lymphocyte–mediated antitumor immunity in poorly immunogenic murine lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2003
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Alternative activation of macrophagesNature Reviews Immunology, 2003
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- The B7–CD28 superfamilyNature Reviews Immunology, 2002
- The role of Fas and FasL as mediators of anticancer chemotherapyDrug Resistance Updates, 2001
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationJournal of Experimental Medicine, 2000
- pH and drug resistance in tumorsDrug Resistance Updates, 2000
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity, 1995
- Platinum Compounds: a New Class of Potent Antitumour AgentsNature, 1969